Hematotoxicity of Holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial PRRT

#3105

Introduction: In patients with neuroendocrine tumor liver metastases, additional tumor reduction can be achieved by sequential treatment with [166Ho]-radioembolization after peptide receptor radionuclide therapy (PRRT).

Aim(s): The aim of this study was to analyse hematotoxicity profiles, with special attention to lymphocytic toxicity.

Materials and methods: All patients included in the prospective clinical HEPAR PLuS study were included in this study. Blood testing was performed at baseline (i.e. prior to [166Ho]-radioembolization) and at regular intervals during one-year follow-up, i.e. at three weeks, six weeks, three months, six months, nine months, and twelve months follow-up. Pre-PRRT laboratory test data were also included. Toxicity was graded using Common Terminology Criteria for Adverse Events (CTCAE v. 4.03). Mixed linear models were used to identify predictors of toxicity.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ebbers S

Authors: Ebbers S, Brabander T, Tesselaar M, Hofland J, Barentsz M,

Keywords: PRRT, NET, neuroendocrine tumor, neuroendocrine neoplasm, lutetium-177-dotatate, radioembolization, holmium-166, hematologic toxicity,